Their technology simplifies the discovery process and accelerates drug development by leveraging phage display and mRNA display to find novel natural peptides and present them to the desired target. This allows clients to identify therapeutic candidates by adopting high throughput affinity and functional screening. Peptides offer the potential to make drugs with the specificity and efficacy of large biologic molecules combined with the smaller dose size, simpler routes of delivery and lower cost of manufacturing found with small molecules, making them uniquely suited to the treatment of chronic diseases which impact large patient populations.